

MAYO CLINIC | Whole Exome Sequencing: LABORATORIES | Ordering Checklist

instructions: Select the box for the test requested on the patient (proband) and complete the corresponding ordering checklist.
☐ Whole Exome Sequencing for Hereditary Disorders or ☐ Whole Exome and Mitochondrial Genome Sequencing
☐ For the patient (proband), order WESDX / Whole Exome Sequencing for Hereditary Disorders, Varies or WESMT / Whole Exome and Mitochondrial Genome Sequencing, Varies.
☐ For each family member specimen that will be submitted as a comparator, order CMPRE / Family Member Comparator Specimen for Exome Sequencing, Varies. Separate orders need to be placed for each family member. Biological parents are the preferred family member comparators; see test catalog for additional information.
Collect patient (proband) and family member specimens. Label specimens with full name and birth date. Do not label family members' specimens with the proband's name. See test catalog for specimen requirements.
☐ Complete the Patient Information form on pages 2–4 (required for all clients).
☐ Complete the signature sections of the Informed Consent on page 7 (required for New York State clients).
☐ If the patient wishes to opt out of receiving secondary findings or change the DNA storage selection, select the appropriate boxes on page 7.
☐ Attach clinic notes from specialists relevant to patient's clinical features.
☐ Attach pedigree.
Send paperwork, clinic notes, and pedigree along with specimens. If not sent with the specimen, fax a copy of the paperwork to 507-284-1759, Attn: WES Genetic Counselors.
☐ Whole Exome Sequencing Reanalysis
☐ For the patient (proband), order WESR / Whole Exome Sequencing Reanalysis, Varies.
☐ Call Mayo Clinic Laboratories at 800-533-1710 and request that WESR is added on to remaining DNA specimen from the original whole exome sequencing test. If the laboratory determines that the patient previously opted out of DNA storage or the specimen was depleted, a new specimen will be requested. See test catalog for specimen requirements.
☐ Complete the following sections of the Whole Exome Sequencing paperwork:
Patient (Proband) Information (page 2)
Provide reason for reanalysis request in Reason for Testing (page 2)
• Provide new information in Suspected Diagnoses (page 3), Patient (Proband) Clinical Evaluations (page 3), and Patient (Proband) Clinical Features (page 4)
Attach clinic notes and/or a pedigree with any relevant new clinical or family history information.

 \square Fax the paperwork, clinic notes, and pedigree to 507-284-1759, Attn: WES Genetic Counselors. Questions: Call with any questions and ask to speak to a WES genetic counselor at 507-293-7299.



Whole Exome Sequencing: Patient Information

Label Here Instructions: Provide the requested information below for appropriate interpretation of the Whole Exome Sequencing test result. In addition, submit relevant clinic notes and pedigree. Patient (Proband) Information (required) Patient Name (Last, First Middle) Birth Date (mm-dd-yyyy) Medical Record No. Sex Assigned at Birth Legal/Administrative Sex ☐ Male ☐ Female ☐ Unknown ☐ Male ☐ Female ☐ Nonbinary **Referring Provider Information** Referring Provider Name (Last, First) Phone Fax* Phone Other Contact/Geneticist/Genetic Counselor (Last, First) Fax* *Fax number given must be from a fax machine that complies with applicable HIPAA regulations. **Reason for Testing** Biological Family Member Information Required information for each family member whose specimen is being sent as a comparator sample. If comparator samples are not being sent, leave blank. The priority should always be to include both parents as comparators, if possible. Contact a genetic counselor at 507-293-7299 to discuss sending more than 2 comparators or comparators that are not first-degree relatives. **Family Member 1 Information** ☐ Sent with proband specimen ☐ To be sent later—must be received within 3 weeks of proband specimen. Testing will proceed at that time with specimens that have been received. Name (Last, First Middle) Medical Record No. Birth Date (mm-dd-yyyy) Sex Assigned at Birth ☐ Male ☐ Female ☐ Unknown Legal/Administrative Sex ☐ Male ☐ Female ☐ Nonbinary Relationship to Proband \square Mother \square Father \square Full sibling \square Maternal half-sibling \square Paternal half-sibling \square Child ☐ Other relatives are accepted on a case-by-case basis; contact a genetic counselor at 507-293-7299 to discuss before ordering testing: Does this relative share any relevant clinical features or clinical history with the patient? \square No \square Yes If "Yes," describe: Family Member 2 Information ☐ Sent with proband specimen ☐ To be sent later—must be received within 3 weeks of proband specimen. Testing will proceed at that time with specimens that have been received. Name (Last, First Middle) Medical Record No. Birth Date (mm-dd-yyyy) Sex Assigned at Birth ☐ Male ☐ Female ☐ Unknown Legal/Administrative Sex ☐ Male ☐ Female ☐ Nonbinary Relationship to Proband \square Mother \square Father \square Full sibling \square Maternal half-sibling \square Paternal half-sibling \square Child ☐ Other relatives are accepted on a case-by-case basis; contact a genetic counselor at 507-293-7299 to discuss before ordering testing: Does this relative share any relevant clinical features or clinical history with the patient? \square No \square Yes If "Yes," describe: **Family Member 3 Information** ☐ Sent with proband specimen To be sent later—must be received within 3 weeks of proband specimen. Testing will proceed at that time with specimens that have been received. Contact the laboratory to discuss sending a third comparator sample. Medical Record No. Name (Last, First Middle) Birth Date (mm-dd-yyyy) Sex Assigned at Birth ☐ Male ☐ Female ☐ Unknown Legal/Administrative Sex ☐ Male ☐ Female ☐ Nonbinary Relationship to Proband \square Mother \square Father \square Full sibling \square Maternal half-sibling \square Paternal half-sibling \square Child Other relatives are accepted on a case-by-case basis; contact a genetic counselor at 507-293-7299 to discuss before ordering testing: Does this relative share any relevant clinical features or clinical history with the patient? \square No \square Yes If "Yes," describe:

Patient Name (Last, First Middle)				Birth Date (mm-dd-yyyy)		
Provide information above or pl	ace label to th	ne right.				
Ancestry						Label Here
☐ African/African American☐ Ashkenazi Jewish☐ East Asian	☐ Europear☐ Latinx☐ Middle Ea		☐ South Asian☐ None of the above☐ Choose not to disclost	□ Unknown		
History of Consanguinity						
☐ No ☐ Yes; relationship de	tails:					
Suspected Diagnoses/	Genes of	Interest	List suspected diagnoses	or specific genes that you v	would like	considered for this evaluation.
Patient (Proband) Clin the specific tests and pertinent	ical Evalu results below	ations Ind . It will be as	dicate the previous tests a ssumed that any evaluatio	and evaluations performed f ns left blank were not perfo	or this pr	oband, and provide details regarding are unknown.
Karyotype	☐ Normal	☐ Abnorn	nal:			
Chromosomal Microarray	☐ Normal					
Gene Sequencing/Panel**	☐ Normal	☐ Abnorn	nal:			
Repeat Expansion	☐ Normal	☐ Abnorn	nal:			
Methylation/UPD**	☐ Normal					
Mitochondrial DNA**	☐ Normal	☐ Abnorn	nal:			
Metabolic Work-up**	☐ Normal					
Brain MRI	☐ Normal					
Brain Spectroscopy	☐ Normal	☐ Abnorn	nal:			
Electroencephalogram (EEG)	☐ Normal	☐ Abnorn	nal:			
Echocardiogram	☐ Normal	☐ Abnorn	nal:			
Electrocardiogram (ECG/EKG)	☐ Normal	☐ Abnorn	nal:			
Skeletal Survey	☐ Normal	☐ Abnorn	nal:			
Renal Imaging	☐ Normal	☐ Abnorn	nal:			
Muscle Biopsy	☐ Normal	☐ Abnorn	nal:			
Electromyogram (EMG)	☐ Normal	☐ Abnorn	nal:			
Ophthalmology Exam	☐ Normal		nal:			
Audiology Evaluation	☐ Normal	☐ Abnorn	nal:			
**Describe details of above evaluations or other evaluations not listed above:						

Page 3 of 7 MC1235-222rev0424

Patient Name (Last, First Middle)		Birth Date (mm-dd-yyyy)	
Provide information above or place	label to the right.		
			Label Here
	al Features Check all that apply to the pati This information is required to facilitate interp		
Perinatal History	Behavioral/Psychiatric	Hearing	
Intrauterine growth restriction	☐ Attention-deficit/Hyperactivity disorder	☐ Conductive hearing loss	Genitourinary
Oligohydramnios	☐ Autism spectrum disorder	☐ Mixed hearing loss	☐ Abnormal external genitalia
☐ Polyhydramnios	☐ Behavioral abnormality; specify below	\square Sensorineural hearing loss	☐ Cliteromegaly
☐ Premature birth	Obsessive-compulsive disorder	Ophthalmologic	☐ Cryptorchidism
Craniofacial	☐ Sleep disturbance	☐ Esotropia	☐ Hydronephrosis
☐ Abnormality of the outer ear	Neuromuscular	☐ High myopia	☐ Renal malformation
☐ Cleft lip	☐ Abnormality of brain morphology;	☐ Nystagmus	Skin/Hair/Dental
☐ Cleft palate	specify below	☐ Ptosis	☐ Abnormal hair; specify below
☐ Craniosynostosis	☐ Ataxia	☐ Strabismus	☐ Abnormal skin; specify below
☐ Facial dysmorphism;	☐ Cerebral palsy		☐ Café-au-lait spot; specify below
specify below	☐ Dystonia	Cardiovascular	☐ Dental abnormalities; specify below
☐ Macrocephaly	☐ Encephalopathy	☐ Aortic dilatation/dissection	☐ Hemangioma
☐ Microcephaly	☐ Gait abnormality	☐ Arrhythmia	☐ Hyperpigmentation
	☐ Hypotonia	☐ Atrial septal defect	_ riyporpigmentation
Growth	☐ Muscle weakness	□ Cardiomyopathy	Endocrine
☐ Failure to thrive	☐ Peripheral neuropathy	☐ Patent ductus arteriosus	☐ Adrenal abnormality
Obesity	☐ Seizures	\square Patent foramen ovale	☐ Hypothyroidism
Overgrowth	☐ Spasticity	☐ Ventricular septal defect	\square Pituitary gland abnormality
☐ Short stature	☐ Tremor	Gastrointestinal	☐ Thyroid gland abnormality
☐ Tall stature		☐ Abnormal GI motility;	Hematologic/Immunologic
Developmental/Cognitive	Musculoskeletal	specify below	☐ Anemia
☐ Absent speech	☐ Arthralgia	☐ Abnormality of the liver;	☐ Bruising susceptibility
☐ Cognitive decline	☐ Contractures	specify below	☐ Immunodeficiency
☐ Developmental regression	☐ Elevated creatine kinase	☐ Dysphagia	☐ Recurrent infections
☐ Global developmental delay	☐ Joint hypermobility	☐ Feeding difficulties	- Recurrent infections
☐ Intellectual disability	☐ Joint laxity	☐ Gastrointestinal inflammation	Cancer/Neoplastic
☐ Motor delay	Pes planus	☐ Nausea and vomiting	\square Specify age of onset and tumor type
☐ Speech delay	☐ Scoliosis	☐ Splenomegaly	
□ opecon delay	☐ Skeletal dysplasia		
	☐ Talipes		
	☐ Vertebral anomaly		
Additional Details/Clinic	eal History		
Additional Details/Clinic	al History		

Page 4 of 7 MC1235-222rev0424

Patient Name (Last, First Middle)	Birth Date (mm-dd-yyyy)

Provide information above or place label to the right.



Whole Exome Sequencing: Informed Consent

Label Here

This form is provided to ensure that you are informed about genetic testing. Genetic testing can be complex. Genetic counseling is recommended to help you more fully understand the risks and benefits associated with this test. It is your choice whether or not to have this test.

What is Whole Exome Sequencing?

- Whole exome sequencing is a test that detects changes (variants) in a patient's genetic code (DNA). Humans have approximately 20,000 genes. Variants in certain important portions of these genes, the exons (coding regions), account for the majority of the variants that cause genetic disorders. Taken together, all of our exons make up the "exome."
- The goal of whole exome sequencing is to identify genetic variants that may provide or confirm a specific diagnosis for a patient.

How is this test performed?

- A blood draw or other procedure will be required to obtain samples from all individuals undergoing testing. DNA is obtained from the samples and sequenced to identify genetic variants.
- The laboratory evaluates certain characteristics of each variant (such as the type of genetic change, whether family members have this change, and how common it is in the general population) in order to determine whether it could cause a genetic disorder in a patient.

What are the potential benefits of this test?

- Genetic variants may be detected that explain a patient's clinical features and provide a diagnosis.
- Establishing a diagnosis may allow for a better prediction of the outcome or course of a disorder. It may also help to determine the best medical management for a patient, such as surveillance, treatment, or preventive measures.
- · Identification of a diagnosis may also allow for a more accurate risk estimate and/or testing of at-risk or affected family members.

What are the potential risks of this test?

- If a disease-causing variant is found and a specific diagnosis is made, it may not change the medical management that was previously recommended. There also may not be a treatment available for the disorder.
- In some cases, a health care provider may recommend additional tests to better understand the results.
- Other possible risks, such as those associated with financial/insurance considerations, psychological effects, and implications for family members should be discussed with your health care provider.

What are the limitations of this test?

- This will not establish a diagnosis for all patients.
- Due to technical limitations, variants may exist in regions that cannot be analyzed.
- · Certain types of variants may not be detected by this test.
- Scientific understanding of the role of genes and variants in human diseases is not complete. Therefore, the significance of some variants that are found may not be known. Patients are encouraged to contact their health care provider for updates regarding their test results, as understanding may change with time.
- The laboratory's interpretation is based upon the accuracy of the clinical information and family history provided by the ordering health care provider. If pertinent information is not provided, this may affect whether certain variants are reported.

What types of test results will the laboratory report?

- Variants in genes associated with the patient's clinical features: Variants in genes known to cause conditions that have features which overlap with the patient's clinical features will be reported (including carrier status for recessive conditions). Variants in these genes will be reported if they are known or expected to cause the genetic condition (pathogenic or likely pathogenic). Variants of uncertain significance in these genes will also be reported.
- Variants in genes of uncertain significance: Variants may be found in genes that are suspected, but not certain, to play a role in human disease. Variants in these genes of uncertain clinical significance may be reported if there is suspicion that they are related to a patient's clinical features.

Page 5 of 7 MC1235-222rev0424

Patient Name (Last, First Middle)	Birth Date (mm-dd-yyyy)	
Provide information above or place label to the right.		
		Label Here
Vill secondary findings be reported?		
Patients are evaluated for medically actionable secondary findings, and the		

- accordance with the American College of Medical Genetics (ACMG) recommendations (Miller et al., 2021). Individuals can choose to not receive secondary findings by opting out on the following page. If an individual opts out of secondary findings, variants in these genes will not be evaluated or reported unless they overlap with the reported clinical features. Note that if the proband opts out, secondary findings will not be reported for any family member.
- · Rarely, findings may implicate another predisposition or presence of active disease. These findings will be carefully reviewed to determine whether or not they will be reported. Multigenic CNVs that are reported in association with the patient's clinical features could include a gene associated with secondary findings.
- Knowledge of a person's risk for these conditions can help to determine the medical actions available to maintain that person's health, such as screening for cancer or specific heart conditions.
- These results may lead to increased anxiety or worry. They may also result in additional medical interventions.

Why it is recommended that family members should be tested and what types of test results will they receive?

- · Interpretation of genetic variants is more accurate when the laboratory is able to compare the results between the patient and their family members.
- · Based on published reports, the chance of finding a diagnosis is highest when samples are submitted from both biological parents. However, the patient alone or in combination with other family members can be submitted.
- Family members will not receive their own full test results. However, if the patient's reported genetic variants are identified in another family member, this will be indicated in the patient's report. Family members may learn about a diagnosis of a genetic condition, increased risk for health concerns, or carrier status for a recessive condition.
- · Variants present in family members that are absent from the patient will not be reported.

What else could the test results reveal about family members?

- It is possible to uncover that a parent or other family member is unrelated to the patient, or that relationships are not as described due to mis-attributed paternity, maternity, or adoption. In this situation, the ordering provider will be notified and options will be discussed.
- In some cases, results may suggest that the parents of a patient are biologically related, such as first cousins or another familial relationship.

What types of test results will the laboratory not report?

- Variants that are benign (not disease causing) or likely benign will not be reported.
- Variants in genes associated with conditions that are not related to a patient's reported clinical features will not be reported, with the possible exception of the secondary findings described above.

What does a negative report mean?

· A negative report means that no variants were reported and an explanation for the patient's clinical features was not identified. However, because of the testing limitations noted above, there may still be a genetic explanation for a patient's features that was not identified by this test.

How will the test results become available?

- The laboratory will release a patient's test report directly to the ordering health care provider and it will become part of the patient's medical record.
- · Requests for the raw data should be directed to the laboratory. A separate fee may apply. The laboratory is not responsible for providing software or other tools needed to visualize, filter, or interpret this data.

Will my test results be shared with databases or researchers?

- · Mayo Clinic is an active participant in the National Institutes of Health-funded Clinical Genome Resource (ClinGen) and shares information about genetic variants identified through clinical genetic testing with publicly available databases, such as ClinVar and Matchmaker Exchange.
- No patient-identifying information (ie, name, birth date) is shared.
- · Genomic data sharing enables health care providers, clinical laboratories, and researchers to share experiences. This can lead to improved interpretations of genetic test results.

What will happen to my DNA after testing is complete?

- The laboratory does not guarantee indefinite storage of patient samples and may discard them within 60 days of test completion, in accordance with statespecific regulations.
- · Any sample remaining after testing is complete may be used for internal laboratory quality control or research purposes, after the removal of patient identifiers such as name and birth date. You may request that your DNA sample not be used for these purposes by indicating this preference on the
- · At this time, it is not standard practice for the laboratory to systematically re-review patient results or previous variant classifications. However, due to broadening genetic knowledge, it is possible that the laboratory may discover new information of relevance to the patient. Should that occur, the laboratory will recontact the healthcare provider to discuss the new findings or classification of previously reported variants; the laboratory may issue an amended report.

Page 6 of 7 MC1235-222rev0424

Provide information above or place label to the right.				
	Label Here			
Informed Consent Signature Page				
Instructions: Informed consent is required for New Yor participation in this test. I understand that the genetic a guarantees my health, the health of an unborn child, or a	nalysis performed by Mayo Clinic I	Laboratories in no way		
Secondary findings:				
 Patient (proband): Checking the "Opt out of secondary findings genes published by ACMG and will not report opts out, secondary findings will not be reported for a be assumed. 	t them unless the variant is in a ger	ne related to the patient's clin	ical features. If the pat	tient (proband)
 Family member comparators: Checking the "Opt out the presence or absence of these variants in the famil be assumed. Family members will not receive their or proband's report. 	y member will not be stated. If the	boxes are not checked or this	s page is not returned,	, opt in will
Patient (Proband) Signature My signature below acknowledges my voluntary partici	pation in this test for myself or my	child.		
Patient/Guardian Signature	Date (mm-dd-yyyy)			
Parent/Guardian Printed Name (Last, First Middle)	Guardian Relationship to	Guardian Relationship to Patient		
Family Member Signatures Only fill out information for family members whose spe	cimens are being sent as comparat	tors.		1
Family Member 1 Signature		Date (mm-dd-yyyy)		☐ Opt out of
Family Member 1 Printed Name (Last, First Middle)	Birth Date (mm-dd-yyyy)		secondary findings	
Family Member 2 Signature	Date (mm-dd-yyyy)		☐ Opt out of	
Family Member 2 Printed Name (Last, First Middle)	Birth Date (mm-dd-yyyy)		secondary findings	
Family Member 3 Signature	amily Member 3 Signature			☐ Opt out of
Family Member 3 Printed Name (Last, First Middle)	mily Member 3 Printed Name (Last, First Middle)			secondary findings
Provider/Genetic Counselor Signature I have explained the above information to this individuo f my ability.	al. I have addressed the limitations	s outlined above and have an	swered all questions	to the best
Provider/Genetic Counselor Signature	Date (mm-dd-yyyy)	Provider/Genetic Counselor Printed Name (Last, First)		
DNA storage:				
 All clients residing outside of New York: Checking the comparators will be destroyed upon completion of the reanalysis be requested in the future, new sample(s) v	is test, and will not be used for res	earch or quality assurance pe	erformed in the labora	tory. Should
New York clients: Checking the "New York clients: pe remaining samples for the proband and any family m				

de-identified samples for research or quality assurance performed in the laboratory. If the box is not checked, all samples from New York clients will be disposed of 60 days after testing is complete and will not be used for research or quality assurance purposes. Should reanalysis be requested in

Birth Date (mm-dd-yyyy)

Patient Name (Last, First Middle)

the future, new sample(s) will be required.

☐ New York clients: permission to retain remaining sample(s)

Page 7 of 7 MC1235-222rev0424